A$288.73
Cochlear is a medical devices business based in Australia. Cochlear shares (COH) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Cochlear has a trailing 12-month revenue of around $2.2 billion. If you're looking to buy shares, check out the steps below.
How to buy shares in Cochlear
To buy shares listed in Australia such as Cochlear, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose or you can see our list of the best share trading platforms in Australia. Then follow these steps.
-
Open and fund your brokerage account. Complete an application with your personal and financial details, including your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
-
Search for Cochlear. Find the share by name or ticker symbol: COH. Research its history to confirm it's a solid investment against your financial goals.
-
Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cochlear reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
-
Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
-
Check on your investment. Congratulations, you own a part of Cochlear. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
Our top pick for
AU stocks
Our top pick for
Copy trading
Our top pick for
Mobile app
Cochlear stock price (ASX:COH)
Use our graph to track the performance of COH stocks over time.Cochlear shares at a glance
52-week range | $234.5377 - $347.7739 |
---|---|
50-day moving average | $309.445 |
200-day moving average | $318.0569 |
Target price | $283.61 |
PE ratio | 51.825 |
Dividend yield | $4.1 (1.49%) |
Earnings per share (TTM) | $5.43 |
Where to buy Cochlear shares
Is it a good time to buy Cochlear stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Cochlear price performance over time
Historical closes compared with the last close of A$287.7
1 week (2024-09-27) | 2.24% |
---|---|
1 month (2024-09-05) | -1.44% |
3 months (2024-07-05) | -10.66% |
6 months (2024-04-05) | -11.86% |
1 year (2023-10-05) | 12.67% |
---|---|
2 years (2022-10-05) | 39.21% |
3 years (2021-10-05) | 34.03% |
5 years (2019-10-04) | 39.10% |
Is Cochlear under- or over-valued?
Valuing Cochlear stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cochlear's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cochlear's P/E ratio
Cochlear's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 52x. In other words, Cochlear shares trade at around 52x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cochlear's EBITDA
Cochlear's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $554.4 million (£0.0 million).
The EBITDA is a measure of a Cochlear's overall financial performance and is widely used to measure stock profitability.
Cochlear financials
Revenue TTM | $2.2 billion |
---|---|
Operating margin TTM | 22.05% |
Gross profit TTM | $1.4 billion |
Return on assets TTM | 11.99% |
Return on equity TTM | 19.88% |
Profit margin | 15.96% |
Book value | 28.102 |
Market capitalisation | $18.4 billion |
TTM: trailing 12 months
N/ACochlear's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Cochlear.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Cochlear's total ESG risk score
Total ESG risk: 24.39
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Cochlear's overall score of 24.39 (as at 12/31/2018) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Cochlear is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Cochlear's environmental score
Environmental score: 3.73/100
Cochlear's environmental score of 3.73 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Cochlear's social score
Social score: 14.34/100
Cochlear's social score of 14.34 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Cochlear's governance score
Governance score: 10.32/100
Cochlear's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Cochlear is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Cochlear's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Cochlear scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Cochlear has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Cochlear Ltd was last rated for ESG on: 2019-01-01.
Total ESG score | 24.39 |
---|---|
Total ESG percentile | 44.88 |
Environmental score | 3.73 |
Environmental score percentile | 2 |
Social score | 14.34 |
Social score percentile | 2 |
Governance score | 10.32 |
Governance score percentile | 2 |
Level of controversy | 2 |
Cochlear share dividends
Dividend payout ratio: 69.06% of net profits
Recently Cochlear has paid out, on average, around 69.06% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.49% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Cochlear shareholders could enjoy a 1.49% return on their shares, in the form of dividend payments. In Cochlear's case, that would currently equate to about A$4.1 per share.
Cochlear's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 16 September 2024 (the "ex-dividend date").
Cochlear share price volatility
Over the last 12 months, Cochlear's shares have ranged in value from as little as $234.5377 up to $347.7739. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Cochlear's is 0.471. This would suggest that Cochlear's shares are less volatile than average (for this exchange).
Cochlear overview
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
Cochlear in the news
Should You Be Adding Cochlear (ASX:COH) To Your Watchlist Today?
Cochlear calls for action in Washington D.C. ahead of World Hearing Day
Are Medical Stocks Lagging Masimo (MASI) This Year?
Frequently asked questions
More guides on Finder
-
Best performing stocks on the ASX in 2024 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
-
Ethical investing in Australia
Ethical investing is predicted to surge in 2024. Here is what you need to know to be part of this growing trend.
-
How to start a share portfolio in Australia
There are 3 main options available to you in Australia if you want to build a portfolio of company stocks
-
Pearler review
Is online broker Pearler the right choice for you? Find out in this guide to Pearler’s fees and features.
-
CommSec vs Selfwealth
We rate the fees and features of both online brokers.
-
How to buy shares for children in 2024
Here is the essential information you need to know about buying shares for children.
-
moomoo Australia review
Gain access to the US and Australian markets for less through moomoo share trading accounts.
-
The cheapest stock brokers in Australia (Oct 2024)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
-
Westpac Share Trading Account review
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.
-
What is a managed fund?
What are managed funds? Read our guide and learn the different types of managed funds available.
Ask a question